NASDAQ:FTH
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. reported net income of −$21.1M in fiscal 2025. Free cash flow was −$20.5M.Summary generated from Faeth Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−74.0%
Debt / equityn/a
Free cash flow−$20.5M
FCF marginn/a
Share count change+0.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −37 | −50 | −37 | −33 | −22 |
| Net income | −37 | −49 | −34 | −30 | −21 |
| Free cash flow | −32 | −39 | −32 | −25 | −20 |
Recent filings
- 8-KDirector or officer change
Sep 17, 2026 - 4Insider transaction report
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KDirector or officer change
Jul 23, 2026 - 4Insider transaction report
Jul 23, 2026 - 8-KEntry into a material agreement
Jun 18, 2026 - 8-KTermination of a material agreement
Jun 15, 2026